News and press releases - Cantargia

* (R) = Regulatory press releases

24 Feb, 2022

(R) Cantargia publishes full year report for 2021

22 Feb, 2022

(R) Cantargia reports encouraging new CAN10 toxicology results and schedules phase I trial for 2023

08 Feb, 2022

Invitation to presentation of Cantargia’s report for the fourth quarter of 2021 on February 24 at 3.00 p.m. CET

04 Feb, 2022

(R) Cantargia reports treatment of first non-squamous non-small cell lung cancer patient in new arm of CANFOUR study

03 Feb, 2022

(R) Cantargia reports positive safety data from CIRIFOUR clinical study on nadunolimab and pembrolizumab combination

19 Jan, 2022

(R) Cantargia reports third party appeal against EPO decision in favor of Cantargia patent

14 Jan, 2022

(R) Cantargia reports treatment of first triple negative breast cancer patient in TRIFOUR study

03 Jan, 2022

(R) Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precision Promise[SM] phase 2/3 clinical trial

29 Dec, 2021

(R) Cantargia reports updated encouraging survival data from CANFOUR trial with nadunolimab and chemotherapy in pancreatic cancer

28 Dec, 2021

Cantargia announces publication of two scientific articles on nadunolimab

<< Newer press releases Older press releases >>

CEO interview, Edison - 2022-03-16

Edison

Panel discussion – Business development

Redeye

CEO interview, Redeye, (In Swedish) - 2021-08-31

Redeye

CEO interview, Di TV (In Swedish) - 2021-05-26

Di TV

CEO presentation AGM (In Swedish) - 2021-05-26

Bio Stock

CEO interview, Redeye, (In Swedish) - 2021-05-24

Redeye

CEO interview, Redeye, (In Swedish) - 2021-05-11

Redeye

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

Pareto Securities

CEO interview, Edison - 2021-03-15

Edison

CEO interview, Redeye, (In Swedish) - 2021-03-09

Redeye

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

Aktiespararna

CEO interview, Edison Open House - 2021-01-26

Edison

CEO interview, direct share issue, Redeye (In Swedish) - 2020-12-16

Redeye

CEO interview, direct share issue, Di TV (In Swedish) - 2020-12-16

Di TV

CEO interview, EFN (In Swedish) - 2020-10-16

EFN

CEO interview, Penser Bank Cancer Research Day (In Swedish) - 2020-10-07

Penser Bank

Article about Cantargias antibody based cancer treatment with multiple functions 2019-10-31

Affärstidningen Näringsliv

Presentation at ASCO 2019, follow up articles and interviews - 2019-07-02

ASCO

Cantargia interview at EFN after ASCO - 2019-06-17

EFN

CEO interview, Edison, London - 2019-02-26

Edison TV

CEO interview, EFN, Lund (In Swedish) - 2018-11-22

EFN

Interview around CAN04 clinical results, Redeye, Stockholm (In Swedish) - 2018-10-23

Redeye

Listing ceremony for Cantargia on Nasdaq Stockholm Main Market - 2018-09-25

Nasdaq

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), EFN, Stockholm (In Swedish) - 2018-09-25

EFN

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), Ditv, Stockholm (In Swedish) - 2018-09-25

Di

CEO interview, Redeye, Stockholm (In Swedish) 2018-09-06

Redeye

CEO interview, BioStock Live, Stockholm (In Swedish) -2018-08-29

Direkt Studios

Småbolagspanelen: Om framtidens cancerbehandlingar, Småbolagsdagen, Stockholm (in Swedish) 2018-06-11

Aktiespararna

CEO interview BioStock Live, Stockholm (In Swedish) -2018-03-20

Direkt Studios

CEO-interview 2017-12-12

Aktiespararna

Interview with Cantargia's CEO Göran Forsberg after the presentation at BioStock Live i Stockholm - 2017-12-04

Direkt Studios

CEO-interview - 2017-11-29

Finwire.tv

Video, interview Göran Forsberg, President Cantargia, Sedermera-dagen, Lund - 2016-03-16

Finwire.tv

© Copyright 2022 · Cantargia AB